Keros Therapeutics Inc (KROS)
Who owns Keros Therapeutics Inc (KROS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 89.9% of the shares are freely tradable; institutional investors hold 96.2%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 12.19 | 2,411,793 | +5.3 | 03/31/2026 |
| Vanguard Group Inc | 7.71 | 1,525,355 | -43.9 | 12/31/2025 |
| Nantahala Capital Management, LLC | 6.87 | 1,360,419 | +277.5 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.20 | 831,421 | +0.0 | 03/31/2026 |
| Orbimed Advisors, LLC | 3.84 | 759,155 | -5.6 | 03/31/2026 |
| Qube Research & Technologies | 3.66 | 724,926 | -7.5 | 03/31/2026 |
| Jacobs Levy Equity Management, Inc. | 3.57 | 706,071 | -8.1 | 03/31/2026 |
| Federated Hermes Inc | 3.48 | 689,229 | +5.3 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 3.45 | 682,043 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 3.62 | 717,071 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Bienaime Jean Jacques | Director | Buy | 1,000 | 10.61 | 10,610 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.